Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 14 | 2018 | 421 | 2.250 |
Why?
|
| Vitamin D Deficiency | 5 | 2018 | 9 | 1.390 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2013 | 58 | 0.740 |
Why?
|
| HIV Seropositivity | 3 | 2018 | 48 | 0.610 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 5 | 0.490 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2015 | 7 | 0.490 |
Why?
|
| Cytomegalovirus | 1 | 2015 | 15 | 0.480 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 34 | 0.480 |
Why?
|
| Antigens, CD | 1 | 2015 | 49 | 0.480 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 44 | 0.480 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 27 | 0.470 |
Why?
|
| Anti-HIV Agents | 3 | 2011 | 60 | 0.470 |
Why?
|
| Vitamin D | 1 | 2013 | 27 | 0.400 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 12 | 0.400 |
Why?
|
| Insulin Resistance | 1 | 2013 | 47 | 0.390 |
Why?
|
| Health Status Disparities | 1 | 2013 | 58 | 0.380 |
Why?
|
| Middle Aged | 13 | 2018 | 7800 | 0.320 |
Why?
|
| Female | 16 | 2018 | 12734 | 0.290 |
Why?
|
| Calcinosis | 1 | 2008 | 43 | 0.290 |
Why?
|
| Coronary Artery Disease | 1 | 2008 | 123 | 0.260 |
Why?
|
| Cross-Sectional Studies | 5 | 2018 | 752 | 0.240 |
Why?
|
| United States | 5 | 2017 | 1741 | 0.240 |
Why?
|
| Risk Factors | 4 | 2013 | 1955 | 0.230 |
Why?
|
| Humans | 17 | 2018 | 22592 | 0.230 |
Why?
|
| RNA, Viral | 4 | 2013 | 42 | 0.230 |
Why?
|
| Male | 12 | 2018 | 12260 | 0.200 |
Why?
|
| Viral Load | 2 | 2013 | 68 | 0.200 |
Why?
|
| Adult | 9 | 2018 | 6826 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2018 | 1476 | 0.170 |
Why?
|
| HIV-1 | 2 | 2013 | 202 | 0.150 |
Why?
|
| Immunosenescence | 1 | 2018 | 3 | 0.140 |
Why?
|
| Fish Oils | 1 | 2018 | 4 | 0.140 |
Why?
|
| Periodontal Attachment Loss | 1 | 2018 | 3 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2013 | 48 | 0.130 |
Why?
|
| Cytokines | 1 | 2018 | 200 | 0.130 |
Why?
|
| Inflammation | 1 | 2018 | 223 | 0.130 |
Why?
|
| Loneliness | 1 | 2017 | 42 | 0.130 |
Why?
|
| Cognitive Aging | 1 | 2017 | 55 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 67 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 244 | 0.110 |
Why?
|
| Aged | 4 | 2017 | 7300 | 0.110 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2013 | 10 | 0.100 |
Why?
|
| Cyclohexanes | 1 | 2013 | 2 | 0.100 |
Why?
|
| Triazoles | 1 | 2013 | 29 | 0.100 |
Why?
|
| Insulin | 1 | 2013 | 77 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2013 | 215 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2013 | 99 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 92 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2013 | 53 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2017 | 1386 | 0.090 |
Why?
|
| Vaginosis, Bacterial | 1 | 2011 | 16 | 0.090 |
Why?
|
| Women's Health | 1 | 2013 | 170 | 0.090 |
Why?
|
| HIV | 1 | 2011 | 39 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 379 | 0.090 |
Why?
|
| Fatty Alcohols | 1 | 2011 | 5 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 147 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2011 | 14 | 0.090 |
Why?
|
| Medically Underserved Area | 1 | 2011 | 13 | 0.090 |
Why?
|
| Disease Progression | 1 | 2013 | 517 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2011 | 13 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 3657 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2011 | 217 | 0.080 |
Why?
|
| Brain | 2 | 2008 | 1123 | 0.080 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 695 | 0.080 |
Why?
|
| Young Adult | 1 | 2013 | 1607 | 0.070 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 8 | 0.070 |
Why?
|
| Drug Resistance, Viral | 1 | 2007 | 12 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2008 | 163 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 281 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 574 | 0.060 |
Why?
|
| Chicago | 2 | 2018 | 788 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 1403 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2018 | 371 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2011 | 123 | 0.040 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2018 | 15 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2018 | 44 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2018 | 54 | 0.040 |
Why?
|
| Prevalence | 1 | 2018 | 372 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 455 | 0.030 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2013 | 1 | 0.030 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2013 | 2 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 10 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2013 | 28 | 0.030 |
Why?
|
| Rectum | 1 | 2013 | 50 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 76 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 41 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 1019 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 27 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 26 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 64 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 53 | 0.020 |
Why?
|
| Urban Population | 1 | 2011 | 124 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 915 | 0.020 |
Why?
|
| Health Behavior | 1 | 2011 | 136 | 0.020 |
Why?
|
| Aging | 1 | 2017 | 1062 | 0.020 |
Why?
|
| Anisotropy | 1 | 2008 | 26 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 800 | 0.020 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2007 | 3 | 0.020 |
Why?
|
| HIV Protease | 1 | 2007 | 4 | 0.020 |
Why?
|
| Affect | 1 | 2008 | 57 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 70 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2007 | 83 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2008 | 265 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 161 | 0.020 |
Why?
|
| Genotype | 1 | 2007 | 246 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 522 | 0.020 |
Why?
|
| Mutation | 1 | 2007 | 327 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2008 | 847 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 789 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 2915 | 0.010 |
Why?
|